PARTICIPA

PARTICIPA

jueves, 28 de septiembre de 2023

Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics. - ScienceDirect

https://www.sciencedirect.com/science/article/abs/pii/S0002870323002806


Enviado desde mi iPhone

No hay comentarios:

Publicar un comentario

Danos tu opinion, enriquece el post.